Real-world evidence and education are key tools that must be used to ensure confidence in biosimilars among US healthcare professionals, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, has told Generics Bulletin in the second part of an exclusive interview.
Having looked ahead to upcoming opportunities for US biosimilars – including a potential global leadership role in ophthalmology – in the first part of the interview (see sidebar), Oskouei turned to some of the challenges to biosimilar uptake and how these could be addressed, including